BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33109495)

  • 1. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Histological Variants on Oncological Outcomes After Surgical Resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-institutional Study.
    Fleury R; Bertail T; Bensalah K; Bernhard JC; Audenet F; Waeckel T; Parier B; Champy C; Olivier J; Doumerc N; Tricard T; Branger N; Bruyere F; Neuville P; Surlemont L; Alexandre Long J; Fontenil A; Vallee M; Roupret M; Boissier R; Jacques Patard J; Durand M; Ouzaid I; Rouget B; Durand X; Joncour C; Belas O; Denise Gomez F; Bigot P; Khene ZE;
    Eur Urol Open Sci; 2024 Apr; 62():123-130. PubMed ID: 38496822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson E; Lam TBL; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Bensalah K; Dabestani S; Bex A
    BJU Int; 2021 Sep; 128(3):386-394. PubMed ID: 33794055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.
    Dabestani S; Beisland C; Stewart GD; Bensalah K; Gudmundsson E; Lam TB; Gietzmann W; Zakikhani P; Marconi L; Fernandéz-Pello S; Monagas S; Williams SP; Torbrand C; Powles T; Van Werkhoven E; Meijer R; Volpe A; Staehler M; Ljungberg B; Bex A
    Eur Urol Focus; 2019 Sep; 5(5):857-866. PubMed ID: 29525381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
    Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
    Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
    Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
    J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes.
    Haddad MM; Schmit GD; Kurup AN; Schmitz JJ; Boorjian SA; Geske J; Thompson RH; Callstrom MR; Atwell TD
    J Vasc Interv Radiol; 2018 Aug; 29(8):1122-1126. PubMed ID: 29887184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
    Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
    Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
    Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
    JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol.
    Siddiqui SA; Frank I; Cheville JC; Lohse CM; Leibovich BC; Blute ML
    BJU Int; 2009 Sep; 104(6):778-85. PubMed ID: 19338559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
    May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
    Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.